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ABSTRACT 
BACKGROUND: Cellular proliferation, driven by cyclin-dependent kinases (CDKs) 
and their cyclin partners, is deregulated in cancer. Antiestrogens, such as tamoxifen, 
antagonize estrogen-induced ERα transactivation of cyclin D1, resulting in reduced 
CDK4/6 activity, p27
Kip1
-mediated inhibition of CDK2 and growth arrest. We 
hypothesized that direct inhibition of CDK2 and 1 may overcome the major clinical 
problem of antiestrogen resistance.  
METHODS: The cellular effects of CDK2/1 siRNA knockdown and purine-based 
CDK2/1 inhibitors, NU2058 and NU6102, were measured in antiestrogen 
sensitive and resistant breast cancer cell lines.  
RESULTS: CDK2 knockdown caused G1 accumulation, while CDK1 depletion 
caused G2/M slowing and dual CDK1/2 depletion resulted in further G2/M 
accumulation and cell death in both antiestrogen sensitive and resistant cells, 
confirming CDK2 and CDK1 as targets for breast cancer therapy. In contrast to 
tamoxifen, which only affected hormone sensitive cells, NU2058 and NU6102 
reduced CDK2-mediated phosphorylation of pRb, E2F transcriptional activity and 
proliferation, ultimately resulting in cell death, in both antiestrogen sensitive and 
resistant cells. Both drugs caused G2/M arrest, reflective of combined CDK2/1 
knockdown, with a variable degree of G1 accumulation.  
CONCLUSION: These studies confirm the therapeutic potential of CDK2 and 1 
inhibitors for cancer therapy, and support their use as an alternative treatment for 
endocrine resistant breast cancer.  
 
Keywords – Breast cancer, CDK, NU2058, NU6102 
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INTRODUCTION 
Antiestrogens, including tamoxifen, are the mainstay of treatment for hormone 
dependent breast cancers.  However, intrinsic and acquired antiestrogen resistance is a 
significant clinical problem (Ali and Coombes, 2002). Tamoxifen competitively 
blocks estrogen-estrogen receptor a (ERa) binding and reduces ERα-mediated 
transcription of cell cycle genes. The mammalian cell cycle is regulated by the 
periodic association of cyclin-dependent kinases (CDKs) with their cyclin partners, 
and kinase inhibitor proteins (e.g. p21
Waf1/Cip1
, p27
Kip1
). G1/S transition is promoted 
by sequential CDK4/6/cyclin D1- and CDK2/cyclin E-mediated phosphorylation of 
the retinoblastoma protein (pRb). Phosphorylation of pRb relieves transcriptional 
repression by the pRb-E2F complex, and disrupts the binding of pRb to E2F, allowing 
E2F activation and the transcription of genes necessary for S phase entry and 
progression. In antiestrogen responsive breast cancers, tamoxifen causes a reduction 
in cyclin D1 expression, reducing CDK4/6 activity and promoting p27
Kip1
/ p21
Waf1/Cip1
 
inhibition of CDK2, resulting in decreased pRb phosphorylation and G1 cell cycle 
arrest (Planas-Silva and Weinberg, 1997).  
 
Estrogen-independent and more aggressive breast cancers tend to have low p27
Kip1 
levels, which is an independent indicator of poor prognosis (Chiarle et al., 2001). 
Transfection of p27
Kip1 
into human mammary tumor cells caused a decrease in cyclin 
E/CDK2 activity, G1 accumulation and suppression of in vivo tumorigenicity (Carroll 
et al., 2003). Ectopic expression of p27
Kip1  
and p21
Waf1/Cip1
 may also inhibit CDK1, 
which plays a critical role at the G2/M boundary, and has recently been implicated in 
G1/S control (Satyanarayana et al., 2008). Therefore the direct targeting of CDK2 and 
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1 may be a useful therapeutic approach, particularly in antiestrogen resistant breast 
cancers (AERBC) where p27
Kip1 
levels are reduced. 
 
Studies in breast cancer have highlighted CDK2 as an essential regulator of estrogen- 
mediated G1/S transition (Cariou et al., 2000; Planas-Silva and Weinberg, 1997); 
however, recent studies in non-breast cancer cell lines and knockout mice have 
questioned the role of CDK2 in cancer cell proliferation (Berthet et al., 2003; Ortega 
et al., 2003; Tetsu and McCormick, 2003). To date, the effects of CDK2 knockdown 
in breast cancer cell lines have not been determined.  Here, we examined the 
consequences of siRNA-mediated CDK2 knockdown in a range of antiestrogen 
sensitive and resistant breast cancer cells. Because reduced CDK2 activity can be 
compensated by CDK1 (Cai D, 2006), we also examined the effects of CDK1 and 
combined CDK2/CDK1 depletion.  The effects of the dual CDK2 and 1 inhibitors 
NU2058 (Arris et al., 2000) and NU6102 (Davies et al., 2002) were also compared to 
combined CDK2 and 1 knockdown. As a model of antiestrogen resistance in the 
clinical setting, we used a parental MCF7 cell line, and compared it to two MCF7 
derived cell sublines: LCC9 and MMU2, generated by selecting for growth in the 
presence of antiestrogens (Brunner et al., 1997; Limer et al., 2006). In addition, the 
effects of CDK1/2 knockdown and inhibition were measured in T47D (tamoxifen 
senstive), MDA-MB-231 and HCC1937 (tamoxifen resistant) cell lines. Overall, the 
results reported in the present study provide the first evidence for the potential use of 
CDK2/1 specific inhibitors in AERBC. 
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METHODS AND MATERIALS 
Materials 
Radiolabelled g[
32
P]ATP (specific activity = 0.37 MBq/ml ) was obtained from 
Amersham Biosciences (Buckinghamshire, UK). NU2058 and NU6102 were 
provided by Professor R. J. Griffin (Northern Institute for Cancer Research, 
Newcastle University, UK), dissolved in DMSO at 100 mM and stored at -20°C. 
Tamoxifen (Sigma) was dissolved in DMSO at 10 mM and stored at -20°C.  
Flavopiridol was provided by the Drug
 
Synthesis and Chemistry Branch, 
Developmental Therapeutics Program,
 
Division of Cancer Treatment and Diagnosis, 
National Cancer
 
Institute (USA). A 50 mmol/L stock solution in DMSO was 
maintained
 
at –20°C. All other chemicals and reagents were from Sigma (Poole, UK) 
unless stated otherwise. Drugs were added to cells in a final DMSO concentration of 
0.1%. 
 
Cell culture 
MCF7, T47D, MDA-MB-231, HCC1937 cells, obtained from the American Tissue 
Culture Collection
 
(Manassas, VA) were grown in RPMI 1640 medium supplemented 
with 10% (v/v) fetal bovine serum, penicillin (50 U/ml) and streptomycin (50 µg/ml) 
unless otherwise stated. MMU2 cells, a tamoxifen-resistant MCF7 derivative 
generated by selection for growth in the presence of tamoxifen (Limer et al., 2006), 
were a gift from Dr Valerie Spiers (University of Leeds, UK). LCC9 cells, an 
antiestrogen-resistant derivative of MCF7 cells selected for growth in the presence of 
the antiestrogen ICI 182,780 and cross-resistant to tamoxifen (Brunner et al., 1997), 
were a gift from Robert Clarke
 
(Georgetown University School of Medicine, USA).  
MMU2 cells were grown in phenol red free RPMI 1640 medium and LCC9 cells in 
 6 
phenol red free Dulbeccos Minimum Essential Medium (Gibco Invitrogen Paisley, 
UK), supplemented with dextran charcoal stripped 10% (v/v) FCS and penicillin (50 
U/ml) and streptomycin (50 µg /ml). Before an experiment MMU2 cells underwent 2 
passages in full RPMI 1640 medium and LCC9 cells underwent 2 passages in full 
Minimum Essential Medium (Gibco Invitrogen.). All cells were grown in fully 
supplemented media during experimental procedures.  
 
Growth inhibition and colony assays 
To measure growth inhibition, cells were exposed
 
to varying concentrations of 
tamoxifen, NU2058 and NU6102  or 0.1% (v/v) DMSO as control for 6 days (3 cell 
doublings) or 7 days for HCC1937 (3 cell doublings), then fixed and stained with 
sulforhodamine B
 
as described previously (Skehan et al., 1990). To measure cell 
survival after 24 hr drug exposure or 72 hr after siRNA, 1000 or 5000 cells seeded in 
10cm dishes. Two weeks post plating cells were fixed with 3:1 methanol:acetic acid 
and stained with 0.4% crystal violet to assess colony formation. The concentration 
required to
 
inhibit cell growth by 50% (GI50), or reduce colony formation by 50% 
(LC50), was calculated from point-to-point
 
graphs using GraphPad Prism (San Diego, 
CA) software.  
 
Cell cycle analysis and western blotting 
Cell cycle analyses and western blotting were carried out as described previously (Cai 
D, 2006). Treatments are described in individual figure legends and for western 
blotting cells were probed with primary antibody (cyclin D1, p27
Kip1
, p21
Waf1/Cip1
 
(Cell Signaling); total pRb (BD Pharmingen); ppRb T821 (Biosource); ppRb 
S807/811 (New England Biolabs); Cyclin D1, p53, ERα (Dako); actin (Sigma); 
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CDK4, CDK2, CDK1, Cyclin A, Cyclin E, total RNA polymerase II (Santa Cruz); 
RNA polymerase
 
II [pSer
2
] (Abcam); RNA polymerase
 
II [pSer
5
] (Covance)). Blots 
were incubated with peroxidase-conjugated swine anti-rabbit or mouse secondary 
antibody (Dako). Chemiluminescence was detected using a dark box with a CCD 
camera (Fuji LAS 3000, Raytek, UK) and quantified using Aida image analyser 
software. 
 
E2F luciferase reporter gene assay 
Cells were transfected with the E2F reporter construct (200 ng) (Hofman et al., 2001) 
together with the b-galactosidase construct (200 ng) (Brady et al., 1999) using 
FuGENE6 transfection reagent (Roche Diagnostics, Lewes, UK) and treated as 
indicated in Figure legends. Luciferase activity was determined following addition of 
50 µl luciferase reagent (Promega, Southampton, UK) using a microplate 
luminometer (Perkin-Elmer, Beaconsfield, UK).  To monitor the transfection 
efficiency, lysates were assayed for b-galactosidase activity by addition of b-
galactosidase reagent and incubated at 37° C for 45 minutes prior to terminating the 
reaction with 1M Na2CO3. Absorbance at 450 nm was read on a microtitre plate 
reader (Bio-Rad, Hemmel Hempstead, UK).  Luciferase activity was normalised to 
the b-galactosidase activity and expressed as a percentage of the DMSO control. 
 
siRNA mediated CDK knockdown 
Cells were seeded in 6 well plates and allowed to adhere for 24 hours. siRNA double 
stranded annealed RNA oligonucleotides: Smart pool siRNA from Dharmacon 
(Chicago, USA) (CDK1 # L-003224-00, CDK2 # L-003236-00), were diluted in full 
media to a final concentration of 20 nM and mixed with RNAifect transfection 
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reagent (Qiagen, Cambridge, UK) then added at 7 µl/ml in RPMI to the cells for 12 
hours before replacing with fresh medium.  
 
CDK immunoprecipitation and kinase assays 
CDK immunoprecipitation and cdk kinase assays were carried out as described 
previously (Cai D, 2006). X-ray films were analyzed and quantified using a CCD 
camera (Fuji LAS 3000, Raytek) and Aida image analyser software.  
 
Statistical analysis 
Statistically significant changes were determined by unpaired Student’s t-test using 
GraphPad Prism software. Statistical significance is given by *; p≤0.05, **; p. ≤0.01, 
***;p≤0.001 
 
 
RESULTS 
Individual and combined CDK2 and 1 depletion results in cell cycle arrest in 
antiestrogen sensitive and resistant breast cancer cell lines.  
First we confirmed the antiestrogen sensitivity status of a panel of breast cancer cell 
lines. MCF7 and T47D cell lines were considered tamoxifen sensitive (GI50 ≤ 3 µM), 
MMU2, LCC9, MDA-MB-231 and HCC1937 were tamoxifen resistant (GI50 > 3 µM) 
(Figure 1).  
 
To evaluate the importance of CDK2 and CDK1 in breast cancer cell growth, and 
their validity as a drug targets in breast cancer, CDK2 and CDK1 protein levels were 
transiently knocked down with siRNA treatment either individually or in combination 
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in exponentially growing breast cancer cell lines. All cell lines showed substantial 
knockdown of CDK2 and CDK1 (Figure 2A). CDK2 knockdown caused significant 
G1 accumulation in MCF7 (1.4-fold**) and LCC9 (1.3-fold,**) with only marginal 
increases in T47D (1.1 fold) and HCC1937 (1.2-fold) cells. There were corresponding 
significant reductions in S phase fractions - MCF7 (1.5-fold**), LCC9 (1.6-fold***), 
T47D (1.4-fold**) and HCC1937 (1.6-fold** ). CDK2 knockdown did not affect the 
cell cycle pattern of MMU2 and MDA-MB-231 cell lines. CDK1 knockdown caused 
very significant G2/M accumulation in all cell lines - MCF7 (2.6-fold***), MMU2 
(1.3-fold **), LCC9 (2-fold***), T47D (1.6-fold**), MDA-MB-231 (2-fold**) and 
HCC1937 (2.3-fold***) cells with co-depletion of both CDK2 and CDK1 together 
causing the greatest increases in G2/M cell cycle fractions - MCF7 (4.8-fold***), 
MMU2 (1.6-fold***), LCC9 (2.8-fold***), T47D (2.8-fold***), MDA-MB-231 (3.3-
fold***) and HCC1937 (2.9-fold***) cell lines (Figure 2B).  
 
CDK2 depletion also reduced colony formation to varying degrees in all cell lines 
(MCF7-23%, MMU2-15%, LCC9-9%, T47D-5% MDA-MB-231-6% and HCC1937-
63% reduction in colony formation). CDK1 depletion further reduced colony 
formation, and to a similar degree in all cell lines (>40%-reduction). Combined 
CDK2 and CDK1 depletion vastly diminished the number of colony forming cells in 
all cell lines (>90%-reduction) (Figure 2C). 
 
CDK1/2 inhibition reduced cell proliferation and colony formation irrespective 
of antiestrogen sensitivity status. 
Combined CDK1/2 depletion caused cell cycle arrest and cell death in both 
antiestrogen sensitive and resistant breast cancer cell lines tested. We therefore set out 
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to investigate if this could be mimicked using small molecule CDK1/2 inhibitors – 
NU2058 and NU6102 (Supplementary Table 1, Supplementary Figure 1). In contrast 
to tamoxifen, NU2058 was approximately equally potent against all breast cancer cell 
lines irrespective of their antiestrogen status with GI50 values ranging between 29 and 
42 µM . NU6102 was a more potent inhibitor of cell growth –with GI50 values of 5 to 
18 µM across the panel (Supplementary Figure 2A, B and Figure 3A). Furthermore, 
NU2058 reduced colony formation, indicative of cell death, with LC50 values ranging 
between 78-94 µM. Likewise, NU6102 reduced cell survival, with LC50 values 
ranging between 6-14 µM (Supplementary Figure 2C, D and Figure 3B). 
 
We next went on to measure the effects of tamoxifen, NU2058 and NU6102 on cyclin 
D1, p21
Waf1/Cip1
, p27
Kip1 
and pRb phosphorylation at T821 – a preferential CDK2-
mediated phosphorylation site (Zarkowska and Mittnacht, 1997). For these studies we 
focused on the parental antiestrogen sensitive MCF7 cell line and its antiestrogen 
resistant derivatives MMU2 and LCC9 cells because a) their common origin provided 
a more similar genotype/phenotype for the characterization of CDK inhibitors and b) 
their derivation mimicked the acquisition of antiestrogen resistance clinically (Figure 
4A).  
 
Exposure of asynchronous cells for 24 hours to tamoxifen at 2 µM (~GI50 in MCF7 
cells) and 8 µM (~GI50 in MMU2 and LCC9 cells (Figure 1) (Johnson et al., 2008) 
reduced cyclin D1 and increased p21
Waf1/Cip1
 and p27
Kip1 
levels, consequently CDK2 
activity was diminished, reflected by decreased pRb
pThr821 
protein levels in parental 
MCF7 cells. Tamoxifen had little or no affect on protein levels measured in MMU2 
and LCC9 cells. There was also little or no change in cyclin D1, p21
Waf1/Cip1
 and 
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p27
Kip1 
levels in all cell lines treated with NU2058 or NU6102. In contrast, 25 µM 
(~GI50 concentration) and 75 µM NU2058 (~GI90 concentration) reduced pRb
pThr821 
levels to a similar extent in all cells.  Exposure to 5 µM NU6102 reduced the levels of 
pRb
pThr821 
in the more sensitive LCC9 cell line (GI50~5 µM); 15 µM NU6102 was 
required to detect reduced pRb
Thr821
 phosphorylation in MCF7 (GI50~15 µM) and 
MMU2 (GI50~10 µM) cells (Figure 4A). Downstream of pRb phosphorylation, E2F 
transcriptional activity was reduced by tamoxifen (2 µM) to a greater extent in MCF7 
cells than the hormone resistant cells, whereas NU2058 (75 µM) and NU6102 (15 
µM) caused similar reductions in all of the cell lines (Figure 4B). 
 
The changes in the levels of phosphorylated pRb and E2F activity were reflected in 
changes in cell cycle distribution (Figure 4C). In MCF7 cells tamoxifen caused a 
concentration-dependent increase in G1 (2 µM - 1.27-fold* and 8 µM - 1.57-fold***,) 
and reduction in S phase (2 µM - 1.17-fold and 8 µM - 1.87-fold**) fraction. 
However in MMU2 and LCC9 cells even at 8 µM tamoxifen only caused a marginal 
increase in G1 accumulation (MMU2  1.1-fold, LCC9 – 1.19-fold) and S phase 
depletion (MMU2 – 8 µM - 1.23-fold, LCC9 – 1.37-fold *).  
 
Treatment with 25 µM NU2058 caused significant G1 accumulation in MCF7 (1.48-
fold*) and LCC9 (1.21-fold*) and a corresponding decrease in S phase fraction in 
MCF7 (2.2-fold*) and LCC9 (1.32-fold*) but no significant change in MMU2 cells. 
Exposure to 75 µM NU2058 caused a further G1 accumulation in LCC9 cells (1.36-
fold***) but G2 accumulation in MCF7 (1.63-fold*) and MMU2 (1.6-fold*) cells. 
However, there was a significant S-phase depletion in all cells; MCF7 (3.44-fold***), 
MMU2 (2.66-fold*) and LCC9 (3.57-fold **). 
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Treatment of asynchronous populations with 5 µM NU6102 arrested cells at the 
G2/M boundary with an increase in G2/M fraction in MCF7 (2.33-fold*), MMU2 
(1.95-fold**) and LCC9 (3.4-fold**) compared to DMSO control. There was little 
further cell cycle perturbation caused by increasing the NU6102 concentration to 15 
µM (Figure 4C).  
 
NU2058 and NU6102 reduce pRb phopshorylation and prevent G1 exit after 
release from serum deprivation. 
We investigated the effects of tamoxifen, NU2058 and NU6102 on the ability of cells 
to transit through G1 into S phase. We first measured pRb phosphorylation at 8 and 
24 hr following release from serum starvation-induced G0/1 arrest (Figure 5A). In 
parental MCF7 cells eight hours after serum addition, pRb
pSer807/811
 levels, indicative 
of CDK4/6 activity (Driscoll et al., 1999), had substantially increased, and by 24 
hours pRb
pSer807/811
 and pRb
pThr821
 levels had fully recovered. Tamoxifen caused a 
significant decrease in pRb phosphorylation at both time points in MCF7 cells. 
Tamoxifen did not alter pRb phosphorylation in MMU2 or LCC9 cells at either time 
point. In contrast, both NU2058 and NU6102 caused concentration dependent 
reductions in pRb phosphorylation after serum release in all three cell lines.  
Tamoxifen significantly reduced serum-stimulated cell cycle re-entry in MCF7 cells 
resulting in a significant concentration-dependent increase in the G1 population (2 
µM – 1.95** and 8 µM – 2.7-fold**) and reduction in S phase fractions (2 µM – 1.2 * 
and 8 µM – 1.75-fold *) compared to the DMSO control. However, in MMU2 and 
LCC9 cells tamoxifen caused only a modest retention in G1 and inhibition of 
progression into S-phase that was not significant. 
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NU2058 had little effect at 25 µM on preventing G1 exit after release from serum 
starvation in any of the cell lines. However 75 µM NU2058 prevented G1 exit in all 
cell lines resulting in a significantly increased G1 fraction in MCF7 (2.74-fold**), 
MMU2 (1.58-fold*) and LCC9 (1.73-fold**) compared to DMSO control and 
reduced S phase entry in MCF7 (2.54-fold*), MMU2 (3.5-fold*) and LCC9 3.8-fold*) 
compared to DMSO control. 
 
The addition of 5 µM NU6102 to synchronous cultures had little effect on MCF7 cell 
cycle distribution. However it caused an increase in G2/M cell cycle fractions in 
MMU2 (2.85-fold*) and LCC9 cells (1.86-fold*) with a corresponding decrease in the 
S phase populations  in MMU2 (2.65-fold***) and LCC9 (1.52-fold**). In contrast to 
asynchronously growing cultures, 15 µM NU6102 arrested synchronised cell 
populations in the G1 phase in all cells; MCF7 (3.34-fold**), MMU2 (1.26-fold) and 
LCC9 1.45-fold*) compared to DMSO control and decreased the S phase fractions in 
MCF7 (3.5-fold*), MMU2 (1.83-fold*) and LCC9 (2.9-fold*) compared to DMSO 
control (Figure 5B). 
 
NU2058 and NU6102 are equipotent CDK2 and CDK1 inhibitors in intact cells.  
Inhibition of human CDK2 and starfish CDK1 by NU2058 and NU6102 has 
previously been described (Arris et al., 2000; Davies et al., 2002; Hardcastle et al., 
2002). Subsequent evaluation of these inhibitors against human CDK1 demonstrated 
that NU6102 is 50-fold more active against CDK2/cyclin E than CDK1/cyclin B 
(IC50= 5 and 250 nM, respectively) and that NU2058 has 1.5 fold selectivity for 
CDK2 /cyclinE  (IC50 = 17 mM) over CDK1 /cyclin B (IC50 = 26 mM) (L-Z Wang 
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unpublished data).  However, treatment of exponentially growing cells with NU2058 
or NU6102 resulted in G2/M arrest typical of combined CDK2 and 1 inhibition. 
We therefore investigated CDK2 and CDK1 inhibition by NU2058 and NU6102 in 
whole cells by immunoprecipitating CDK2 and 1 from intact MCF7 cells that had 
been treated with the inhibitors for 1 hr and measuring their ability to phosphorylate 
Histone H1. The concentrations required to inhibit CDK2 by 50% were estimated as 
54 µM for NU2058 and 9 µM for NU6102 by quantitative densitometry (Figure 6A). 
Strikingly, similar concentrations were required to inhibit CDK1 by 50%, i.e., 65 µM 
for NU2058 and 11 µM for NU6102 (Figure 6B). Therefore, despite their selectivity 
for CDK2 in enzymatic assays, in MCF7 cells, both compounds were equipotent 
against cellular CDK2 and CDK1.  Importantly, cell growth inhibition by NU2058 
and NU6102 (Figure 3) was observed at concentrations that inhibited CDK2 and 
CDK1 in intact cells. 
 
To determine the effects of these compounds on the activity of the transcriptional 
CDKs, we measured p53 accumulation and levels of RNA polymerase II 
phosphorylation.  Neither NU2058 (25 and 75 mM) nor NU6102 (5 and 15 mM) 
affected phospho Serine 2 or 5-RNA polymerase II or p53 levels indicating they were 
not inhibiting the activity of transcriptional CDKs in cells (Figure 6C). In contrast, 
flavopiridol, a potent CDK9 inhibitor, did reduce RNA polymerase II phosphorylation 
and increased p53 levels. Furthermore, when CDK1/2 depleted cells were treated with 
NU2058 and NU6102 and cell survival measured, there was no further reduction in 
colony formation compared to CDK1/2 knockdown alone. This provides additional 
evidence, that inhibition of CDK1 and CDK2 is the mechanism by which NU2058 
and NU6102 kill breast cancer cells (Figure 6D). 
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DISCUSSION  
The development of resistance to hormonal therapies is a major problem in the 
treatment of breast cancer. Since antiestrogen therapy results in a reduction in cyclin 
D1 levels and p21
Waf1/Cip1
/p27
Kip1
 mediated inhibition of CDK2/1 activity, we sought 
to determine the ability of the novel guanine based CDK2/1 inhibitors NU2058 and 
NU6102 to target CDK2 and CDK1 and assess their therapeutic potential as 
alternatives to hormonal therapy in breast cancer. CDK2 and 1 were validated as 
therapeutic targets using transient siRNA knockdown. Studies in other cancer cell 
lines measuring cell cycle effects of individual CDK2 depletion showed little change 
in cell cycle profiles of asynchronous cells due to compensation by other CDK family 
members, including CDK1 and CDK4/6 (Cai D, 2006). However, our data show that 
in breast cancer cells CDK2 depletion resulted in G1 accumulation, and a reduction in 
the S phase fractions in both tamoxifen-sensitive MCF7 and T47D cells, and resistant 
LCC9 and HCC1937 cells, indicating CDK2 knockdown or inhibition may not be as 
easily compensated in all cell types, and may play an important role in G1 progression 
in breast cancer cells compared to other types of cancer cells. Furthermore CDK2 
depletion resulted in partial cell death in these cell lines, in particular, CDK2 
depletion caused a large reduction in colony formation in the antiestrogen resistant-
BRCA1 mutant HCC1937 cells.  BRCA1 depleted breast cancer cells have previously 
been shown to be sensitive to CDK2 depletion or inhibition (Deans et al., 2006). 
Moreover, MCF7 cells which developed antiestrogen resistance through loss of pRb 
expression, had increased cyclin A expression and CDK2 activation, and were still 
highly dependent on CDK2, but not CDK4 activity for proliferation (Varma et al., 
2007). These studies suggest CDK2 inhibition may be of therapeutic value for several 
subgroups of antiestrogen resistant breast cancer.  
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CDK1 depletion reduced colony formation to a greater extent than CDK2 depletion, 
probably due to the inability of CDK2 to fully compensate for CDK1 loss (Johnson et 
al., 2009). Combined CDK1 and CDK2 depletion caused massive reduction in colony 
formation in all cell lines, suggesting that small molecule inhibition of CDK1 and 2 
may be an affective strategy for treatment of both antiestrogen sensitive and resistant 
breast cancer populations. 
 
After establishing that combined CDK2 and CDK1 depletion resulted in cell cycle 
arrest and cell death in both antiestrogen sensitive and resistant breast cancer cells, we 
investigated if similar effects could be achieved by reducing CDK activity with small 
molecule inhibitors. The antiestrogen resistant cells were 3-5x less sensitive to 
tamoxifen compared to MCF7 cells and between 1.5 and 2.5x less sensitive than 
T47D cells. However, there was very little difference in the sensitivity of the cells to 
NU2058 and NU6102 for both inhibition of cell proliferation and induction of cell 
death. Of note, MMU2 and LCC9 cells were more sensitive to NU6102 compared to 
their parental-MCF7 cells. The progression to antiestrogen resistance, selects for 
further deregulation of cell cycle proteins such as p27
 Kip1
 or pRb (Arteaga, 2004; 
Varma et al., 2007), resulting in an increased dependency on CDK activity for 
survival, and potentially rendering these cells more sensitive to CDK inhibition.   
 
Investigation of the underlying mechanisms of cell growth arrest, focused on MCF7 
cells and its antiestrogen resistant derivatives, MMU2 and LCC9 cells, revealed that, 
in contrast to tamoxifen, to which only MCF7 cells responded, NU2058 and NU6102 
directly reduced pRb
pThr821
 phosphorylation, E2F transcriptional activity and cell 
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growth in all of the cells. Both compounds had little affect on cyclin D1, p21
Waf1/Cip1
 
or p27
Kip1
 levels, indicating the reduction in pRb phosphorylation and cell 
proliferation were a result of directly inhibiting CDK activity. Of note, at 15 µM 
NU6102, total pRb protein levels were also reduced in all MCF7 cell types. This 
concentration resulted in cell death by colony assay, therefore total pRb was probably 
reduced as a consequence of cells beginning to die. Further investigation revealed that 
the inhibitors did prevent S-phase re-entry after G0/G1 release, consistent with CDK2 
inhibition, but that in asynchronous cells they caused predominantly G2/M arrest, 
which was more indicative of dual CDK1 and 2 inhibition (Cai D, 2006). We had 
previously observed that NU6102 inhibited CDK1-dependent nucleolin 
phosphorylation and CDK2-dependent pRb phosphorylation with equal efficiency in 
MCF7 cells (Davies et al., 2002), and other studies show that 8 μM NU6102 inhibited 
CDK1-dependent phosphorylation in prostate cancer cells (Chen et al., 2006). We 
therefore investigated the effect of NU2058 and NU6102 on CDK1 and 2 kinase 
activity in intact cells. We showed that neither inhibitor was selective for CDK2 
versus CDK1 inside cells, with both enzymes being inhibited by 50% by about 60 μM 
NU2058 and 10 μM NU6102. Furthermore, in contrast to data from enzymatic assays, 
higher concentrations of NU2058, and in particular NU6102, were required to inhibit 
cellular CDK1 and 2. Similar discrepancies between the concentrations required for 
enzyme inhibition in cell-free and whole cell assays have been demonstrated for a 
range of CDK inhibitors (Pevarello et al., 2005). Importantly, the concentrations of 
NU2058 and NU6102 required to inhibit cell proliferation by 50% were broadly 
similar to the concentrations required to inhibit CDK1 and 2 in intact cells. These 
compounds did not induce p53 accumulation or reduce RNA polymerase II 
phosphorylation at the concentrations tested, indicating that growth inhibition was not 
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due to inhibition of transcriptional CDKs but was a result of direct inhibition of only 
CDK2 and CDK1. Furthermore there was no increase in cell death when CDK1 and 2 
depleted cells were treated with NU2058 or NU6102. These data provide strong 
evidence that the affects of NU2058 and NU6102 on breast cancer cell survival were 
mediated through inhibition of only CDK2 and CDK1. 
 
In summary, we have validated CDK2 and 1 as therapeutic targets in antiestrogen 
sensitive and resistant breast cancer cells by demonstrating G1 and G2/M 
accumulation following CDK2, CDK1 or combined CDK knockdown, respectively. 
In addition, we have shown that the dual CDK1 and CDK2 inhibitors NU2058 and 
NU6102 similarly induce cell cycle arrest and death.  Importantly, these compounds 
inhibit the proliferation of breast cancer cell lines independent of their genetic 
backgrounds or sensitivity to antiestrogens. These data provide the ‘proof of 
principle’ evidence that small molecule CDK2/1 inhibitors could be a useful 
alternative treatment for breast cancer patients with endocrine resistant disease.   
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FIGURE LEGENDS  
 
Figure 1. Effect of tamoxifen on breast cancer cell lines growth. 
(A) Inhibition of breast cancer cell growth by tamoxifen after 6 days. Data are mean 
and S.E of three independent experiments. Left; Graphs demonstrating MCF7, MMU2 
and LCC9 cell growth inhibition. Right; MCF7, T47D, MDA-MB-231 and HCC1937 
cell growth inhibition.  
(B) Tamoxifen concentrations required to inhibit breast cancer cell growth by 50% of 
that of vehicle treated control over a 6 day period. Bars show mean and S.E 
concentrations from 3 independent experiments.  
 
Figure 2. Effect of CDK2, CDK1 and combined CDK2/1 siRNA on cell cycle 
profile and cell survival. 
 A) Representative examples of western blot showing CDK2 and CDK1 levels 
prepared 72 h post transfection of either scrambled (Sc), CDK2 (K2), CDK1 (K1), 
CDK1 and CDK2 (K1/2) siRNA in asynchronously growing breast cancer cells.  
B) Cell cycle analysis data pooled from 3 independent experiments expressed as the 
mean G1 (solid bar), S (open bar), G2/M (grey bar) cell cycle fractions of cells treated 
as for Figure 2A.    
C) Mean and S.E colony formation for cells treated as in 2A, colony formation was 
assessed 2 weeks post transfection. 
 
Figure 3. NU2058 and NU6102 concentrations required to inhibit breast cancer 
cell lines growth and reduce cell survival by fifty percent. 
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(A) Concentrations required to inhibit cell growth by 50% of that of vehicle treated 
control over a 6 day period. Bars show mean and S.E concentrations from 3 
independent experiments. Left; NU2058. Right; NU6102. 
(B) Concentrations required to reduce colony formation by 50% of that of vehicle 
treated control. Cells were treated with NU2058 or NU6102 for 24 hours and then 
replated, 2 weeks later colony formation was assessed. Bars show mean and S.E 
concentrations from 3 independent experiments. Left; NU2058. Right; NU6102. 
 
Figure 4. Cell cycle effects of tamoxifen, NU2058 or NU6102 on asynchronously 
growing MCF7 cell lines.  
A) Representative western blot of cyclin D1, p21
Waf1/Cip1
, p27
Kip1
,  ppRb T821 and 
total pRb protein levels in asynchronously growing MCF7, MMU2 and LCC9 cells 
exposed to 2 or 8 µM tamoxifen, 25 or 75 µM NU2058, 5 or 15 µM NU6102 for 24 h 
and compared to 0.1% (v/v) DMSO control.    
B) E2F activity in cells transfected with an E2F luciferase reporter construct and a β-
gal reporter plasmid. Relative luciferase activity was then expressed as a percentage 
of the DMSO treated control. Data are mean ± SE from 3 independent experiments. 
C) Flow cytometric analyses of cells treated with tamoxifen and CDK2/1 inhibitors 
expressed as the mean G1 (solid bar), S (open bar), G2/M (grey bar) cell cycle 
fractions from 3 independent experiments. 
 
Figure 5. Effect of tamoxifen, NU2058 or NU6102 on phosphorylated pRb levels 
and cell cycle distribution in synchronously growing MCF7 cell lines.  
A) Phosphorylated and total pRb in lysates of exponentially growing cells (+), cells 
serum starved for 24 h (-) or serum starved for 24 h and released into full medium in 
 26 
the presence of 0.1% (v/v) DMSO, 2 or 8 µM tamoxifen, 25 or 75 µM NU2058, 5 or 
15 µM NU6102 for 8 and 24 h post release.   
B) Flow cytometric analysis of cells treated as described in 5A and harvested at 24 hr 
after serum release expressed as the mean G1 (solid bar), S (open bar), G2/M (grey 
bar) cell cycle fractions from 3 independent experiments. 
 
Figure 6. Effect of NU2058 or NU6102 on CDK2 and CDK1 kinase activity, p53 
and RNA polymerase II phosphorylation levels in MCF7 cells. 
A) CDK2 and (B) CDK1 immunoprecipitated from control MCF7 cells or those 
treated with NU6102 or NU2058 for 1 hour. Immunoprecipitated CDK levels were 
analyzed by western blotting and kinase activity measured by CDK kinase assay. 
CDK protein was incubated with γ[
32
P]ATP and histone H1 and analyzed by SDS-
PAGE and autoradiography. 
C) Western blot for p53, phospho Serine 2 and 5 of RNA polymerase II and total 
RNA polymerase II protein levels measured in MCF7 cells. Lysates were collected 16 
hrs after exposure of exponentially growing cells to NU2058 (25 and 75 μM), 
NU6102 (5 and 15 μM) and flavopiridol (0.5 μM).  
D) MCF7 cells were transfected with either scrambled or CDK1 and 2 siRNA, 3 days 
post-transfection cells were treated with either DMSO, NU2058 or NU6102 for 24 
hours followed by replating. Colony formation was assessed 2 weeks after replating. 
Graph shows mean and S.E colony formation relative to the scrambled-DMSO treated 
control plates. 
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Supplementary Figure Legends 
 
Supplementary Figure 1. Left; NU2058 and Right; NU6102 chemical structure. 
 
Supplementary Figure 2. Inhibition of breast cancer cell growth and survival by 
NU2058 and NU6102. 
A) Cells treated as for Figure 3A. Graph shows mean and S.E cell growth inhibition 
by NU2058 in Left; MCF7, MMU2 and LCC9 cells, and Right; MCF7, T47D, MDA-
MB-231 and HCC1937 cells. 
B) Cells treated as for Figure 3A. Graph shows mean and S.E cell growth inhibition 
by NU6102 in Left; MCF7, MMU2 and LCC9 cells, and Right; MCF7, T47D, MDA-
MB-231 and HCC1937 cells. 
C) Cells were treated as for Figure 3B. Graph shows mean and S.E cell survival 
assessed by colony formation 2 weeks post-24 hours treatment with NU2058 in Left; 
MCF7, MMU2 and LCC9 cells, and Right; MCF7, T47D, MDA-MB-231 and 
HCC1937 cells.  
D) Cells were treated as for Figure 3B. Graph shows mean and S.E cell survival 
assessed by colony formation 2 weeks post-24 hours treatment with NU6102 in Left; 
MCF7, MMU2 and LCC9 cells, and Right; MCF7, T47D, MDA-MB-231 and 
HCC1937 cells.  
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Tables 
Supplementary Table 1. NU2058 and NU6102 in vitro kinase inhibition.  
Kinase NU2058 IC 50 or % 
inhibition 
NU6102 IC 50 or % 
inhibition 
CDK1/cyclin B 26 mM 0.25 mM 
CDK2/cyclin A3 17 mM 0.005 mM 
CDK4/cyclin D1 33% at 100 mM 1.5 mM 
CDK5/p25 50% at 100 mM 0.48 mM 
CDK7/cyclin H 44% at 100 mM 4.4 mM 
CDK9/cyclin T 43% at 100 mM 1.1 mM 
Kinases with IC50 values 
of <1 mM (IC50 value) 
- ROCK II (0.59 mM) 
PDK1 (0.85 mM) 
DYRK1a (0.95 mM) 
Kinases inhibited at 10 mM 
(100 mM ATP): 
 
75-100% inhibition 
 
 
51-75% inhibition 
 
 
 
25-50% inhibition 
 
 
 
- 
 
 
- 
 
 
 
AMPK, PI3K 
 
 
 
AMPK, CHK1, GSK3b, 
Lck, CSK, PI3K 
 
JNK, MAPKAP2, MEK1, 
PRAK, SAPK2a, 
SAPK2b, SAPK4, SGK 
 
ERK2, p70 S6K, Phos 
kinase, PKA, PKBa, CK1 
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